Dogwood (DWTX) Therapeutics filed for new intellectual property protection for synthetic Halneuron. If granted, the IP’s exclusivity period will extend to 2045, before additional patent term restoration extensions.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DWTX:
- Dogwood Therapeutics Approves Equity Plan Amid Business Merger
- Dogwood enrolls first 100 patients in Halneuron Phase 2b trial
- Strategic Acquisitions and Promising Trials Bolster Buy Rating for Dogwood Therapeutics
- Dogwood Therapeutics Advances Pain Treatment Pipeline
- Dogwood reports Q3 EPS ($8.20) vs ($2.05) last year